Display options
Cite
Kuba MG, Xu B, D'Angelo SP, et al. The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. Histopathology. 2021;79(5):836-846doi: 10.1111/his.14433.
Kuba, M. G., Xu, B., D'Angelo, S. P., Rosenbaum, E., Plitas, G., Ross, D. S., Brogi, E., & Antonescu, C. R. (2021). The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. Histopathology, 79(5), 836-846. https://doi.org/10.1111/his.14433
Kuba, Maria Gabriela, et al. "The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast." Histopathology vol. 79,5 (2021): 836-846. doi: https://doi.org/10.1111/his.14433
Kuba MG, Xu B, D'Angelo SP, Rosenbaum E, Plitas G, Ross DS, Brogi E, Antonescu CR. The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. Histopathology. 2021 Nov;79(5):836-846. doi: 10.1111/his.14433. Epub 2021 Sep 05. PMID: 34165212; PMCID: PMC8678905.
Copy Download .nbib Format: NLM
Share it on

Histopathology. 2021 Nov;79(5):836-846. doi: 10.1111/his.14433. Epub 2021 Sep 05.

The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast.

Histopathology

Maria Gabriela Kuba, Bin Xu, Sandra P D'Angelo, Evan Rosenbaum, George Plitas, Dara S Ross, Edi Brogi, Cristina R Antonescu

Affiliations

  1. Department of Pathology, Memorial Sloan Kettering Cancer Center, USA.
  2. Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
  3. Department of Medicine, Weill Cornell Medical Center, USA.
  4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 34165212 PMCID: PMC8678905 DOI: 10.1111/his.14433

Abstract

AIMS: Radiation-associated angiosarcomas (RT-ASs) of the breast are rare tumours with a poor prognosis. MYC gene amplification is considered to be the hallmark of RT-AS, and is sometimes used as a diagnostic tool to distinguish it from other radiation-associated vascular lesions. However, a small subset of RT-ASs lacks MYC amplification, and this may be associated with better outcome. Loss of trimethylation at lysine 27 of histone 3 (H3K27me3) expression by immunohistochemistry (IHC) has been recently postulated as an additional diagnostic marker for RT-AS. The aims of this study were to evaluate the impact of MYC amplification as detected by fluorescence in-situ hybridisation and/or next-generation sequencing on clinicopathological features and outcome in a large cohort of RT-ASs, compare outcome with those of radiation-associated sarcomas (RT-Ss) of the breast other than angiosarcoma, and evaluate expression of H3K27me3 IHC in these groups.

METHODS AND RESULTS: Eighty-one RT-ASs were identified, including 73 that were MYC-amplified and 8 (10%) that were MYC-non-amplified. MYC-amplified RT-ASs were diagnosed in older patients (median age, 69 years versus 61 years). The 5-year disease-specific survival and 5-year overall survival rates were 56% and 47%, respectively. Older age, larger tumour size, positive margin and MYC amplification were associated with worse prognosis. None of the RT-ASs showed complete loss of H3K27me3 IHC expression. All 18 RT-Ss were MYC-non-amplified, and complete loss of H3K27me3 expression was seen in 2 cases. We found no difference in prognosis between RT-AS and RT-S.

CONCLUSIONS: RT-AS of the breast is associated with a poor prognosis. Older age at diagnosis, larger tumour size, positive margin at excision and MYC amplification are associated with worse prognosis.

© 2021 John Wiley & Sons Ltd.

Keywords: MYC ; angiosarcoma; breast; radiation-associated sarcomas

References

  1. Nat Rev Cancer. 2002 Oct;2(10):764-76 - PubMed
  2. Am J Surg Pathol. 2004 Jun;28(6):781-8 - PubMed
  3. Am J Surg Pathol. 2008 Jun;32(6):943-50 - PubMed
  4. Genes Chromosomes Cancer. 2013 Jan;52(1):93-8 - PubMed
  5. Breast Cancer Res Treat. 1998 Jan;47(2):101-9 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):425-435 - PubMed
  7. Hum Pathol. 2015 Jun;46(6):868-75 - PubMed
  8. Histopathology. 2020 Oct;77(4):667-672 - PubMed
  9. J Mol Diagn. 2017 Mar;19(2):244-254 - PubMed
  10. Mod Pathol. 2012 Jan;25(1):75-85 - PubMed
  11. Genes Chromosomes Cancer. 2011 Jan;50(1):25-33 - PubMed
  12. Virchows Arch. 2018 Mar;472(3):361-368 - PubMed
  13. Histopathology. 2017 Feb;70(3):385-393 - PubMed
  14. Am J Surg Pathol. 2008 Dec;32(12):1896-904 - PubMed
  15. Histopathology. 2021 Jan;78(2):321-326 - PubMed
  16. J Mol Diagn. 2015 May;17(3):251-64 - PubMed
  17. Am J Pathol. 2010 Jan;176(1):34-9 - PubMed
  18. Am J Surg Pathol. 2005 Aug;29(8):983-96 - PubMed
  19. Cancer Radiother. 2015 May;19(3):168-74 - PubMed
  20. JAMA Oncol. 2019 Feb 1;5(2):267-269 - PubMed
  21. Genes Chromosomes Cancer. 2012 Jun;51(6):569-78 - PubMed
  22. Histopathology. 1997 Aug;31(2):189-95 - PubMed
  23. Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):113-9 - PubMed
  24. Hum Pathol. 2014 Apr;45(4):709-16 - PubMed
  25. Am J Surg Pathol. 2016 Apr;40(4):479-89 - PubMed
  26. Histopathology. 2020 Aug;77(2):293-302 - PubMed
  27. Breast Cancer Res Treat. 2015 May;151(1):131-40 - PubMed

Publication Types

Grant support